| pubmed-article:15355903 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15355903 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:15355903 | lifeskim:mentions | umls-concept:C0332174 | lld:lifeskim |
| pubmed-article:15355903 | lifeskim:mentions | umls-concept:C0746319 | lld:lifeskim |
| pubmed-article:15355903 | lifeskim:mentions | umls-concept:C0060133 | lld:lifeskim |
| pubmed-article:15355903 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:15355903 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:15355903 | lifeskim:mentions | umls-concept:C0796419 | lld:lifeskim |
| pubmed-article:15355903 | pubmed:issue | 17 | lld:pubmed |
| pubmed-article:15355903 | pubmed:dateCreated | 2004-9-9 | lld:pubmed |
| pubmed-article:15355903 | pubmed:abstractText | To develop a potentially superior adjuvant chemotherapy regimen, we conducted a pilot study of dose-dense 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by weekly alternating taxanes. The primary objective was to determine the feasibility of the regimen; the secondary objective was to estimate the disease-free and overall survival. | lld:pubmed |
| pubmed-article:15355903 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15355903 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15355903 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15355903 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15355903 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15355903 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15355903 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15355903 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15355903 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15355903 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15355903 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15355903 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:15355903 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:SeidmanAndrew... | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:PanageasKathe... | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:NortonLarryL | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:RobsonMark... | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:HudisClifford... | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:DangChau TCT | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:FornierMonica... | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:HurriaArtiA | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:TheodoulouMar... | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:LakeDianaD | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:DicklerMaura... | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:D'AndreaGabri... | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:MoynahanMary... | lld:pubmed |
| pubmed-article:15355903 | pubmed:author | pubmed-author:CurrieViolant... | lld:pubmed |
| pubmed-article:15355903 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15355903 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:15355903 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:15355903 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15355903 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15355903 | pubmed:pagination | 5754-61 | lld:pubmed |
| pubmed-article:15355903 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:meshHeading | pubmed-meshheading:15355903... | lld:pubmed |
| pubmed-article:15355903 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15355903 | pubmed:articleTitle | Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. | lld:pubmed |
| pubmed-article:15355903 | pubmed:affiliation | Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. dangc@mskcc.org | lld:pubmed |
| pubmed-article:15355903 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15355903 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15355903 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15355903 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15355903 | lld:pubmed |
